
Sign up to save your podcasts
Or


Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes a wide range of options for best managing patients with advanced NSCLC who experience acquired resistance, the progression of cancer after a good initial response to a targeted therapy.
By cancerGRACE - H. Jack West, MD5
11 ratings
Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes a wide range of options for best managing patients with advanced NSCLC who experience acquired resistance, the progression of cancer after a good initial response to a targeted therapy.

2 Listeners

0 Listeners

0 Listeners

0 Listeners

1 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners